Title: 225Ac and 213Bi alpha-Particle-Emitter Therapy in Combination with SAHA and 17-AAG
Citation: World Journal of Nuclear Medicine vol. 12 no. Supplement 1 p. 48 (Paper n° O-013)
Publisher: Medknow
Publication Year: 2013
JRC N°: JRC80889
ISSN: 1450-1147 (print), 1607-3312 (online)
URI: www.wjnm.org
Type: Articles in periodicals and books
Abstract: Alpha-particle emitter radiopharmaceutical therapy (alpha-RPT) is a promising approach to cancer therapy. Alpha-particles lead to highly disruptive and largely irreparable deoxy ribonucleic acid (DNA) double strand breaks capable of killing a cell with as few as one to two tracks through the nucleus. Although the ability to repair alpha-induced DNA damage is independent of alpha-dose-rate the efficacy of alphaemitter with a long half-life can be compromised when targeting very rapidly proliferating tumor cells if the dose-rate is outpaced by the proliferation rate. In this study, we investigate alpha-particle emitter radiopharmaceutical therapy (alpha-RPT) using 225Ac (T1/2=10 days) and 213Bi (T1/2=45.6 min) in combination with clinically approved tumor growth suppressor, suberoylanilide hydroxamic acid (SAHA) and cell cycle blocker, 17-(Allylamino)-17-demethoxy- geldanamycin (17-AAG) in breast cancer cells.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.

Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.